Browsing Tag
EYLEA
6 posts
Biocon Biologics (NSE: BIOCON) clears global aflibercept deal with Regeneron, Bayer for Yesafili rollout
Biocon Biologics secures global aflibercept launch rights for Yesafili after Regeneron–Bayer settlement. Find out what this means for biosimilar strategy.
Can Celltrion’s Eydenzelt disrupt Canada’s aflibercept market after Health Canada approval?
Celltrion secures Health Canada approval for Eydenzelt, its aflibercept biosimilar. Explore how it aims to disrupt Canada’s high-cost eye care drug market.
Celltrion’s Eydenzelt gets FDA nod — Is Eylea finally facing a real biosimilar rival?
Find out how Celltrion’s FDA-approved Eydenzelt is set to challenge Eylea and reshape the biosimilar landscape for retinal diseases in 2025.
Biocon Biologics gets Health Canada approval for Yesafili aflibercept biosimilar
Biocon Biologics wins Health Canada approval for Yesafili, its 10th biosimilar. Find out how this launch could reshape retinal care access in Canada.
Can Biocon Biologics lead biosimilar disruption in ophthalmology with Yesafili?
Biocon Biologics secures 2026 U.S. launch for Yesafili, its interchangeable biosimilar to Eylea. Find out how this reshapes eye care access and competition.
FDA approves updated label for Regeneron’s EYLEA treating wet AMD
In a significant development for ophthalmic care, Regeneron Pharmaceuticals has received approval from the U.S. Food and Drug…